Evaluation of Chemotherapy-induced Dysgeusia in Patients With Gastrointestinal Cancer: A Pilot Study
- PMID: 37369461
- PMCID: PMC10347957
- DOI: 10.21873/invivo.13283
Evaluation of Chemotherapy-induced Dysgeusia in Patients With Gastrointestinal Cancer: A Pilot Study
Abstract
Background/aim: Dysgeusia, one of the adverse effects of cancer chemotherapy, and anorexia due to taste disorder can significantly impair the quality of life of patients. However, an evaluation method for dysgeusia has not yet been established. The present prospective study aimed to utilize a combination of subjective and objective assessment methods to evaluate dysgeusia in patients with gastrointestinal cancer initiating chemotherapy, to determine chemotherapeutic drugs and regimens causing dysgeusia, and to assess whether dysgeusia was associated with zinc deficiency.
Patients and methods: A total of 21 patients with newly diagnosed gastrointestinal cancer were registered between August 2020 to March 2021. The following regimens were also included in the evaluation if the patients did not develop dysgeusia. A total 30 regimens were administered to the patients during the study period. A salt-impregnated test paper (Salsave®) was used as a subjective assessment, and the chemotherapy-induced taste alteration scale was used as an objective assessment.
Results: Based on physician interviews, dysgeusia was diagnosed in 8 of 21 patients (38%) treated with 8 of 30 regimens (27%). All regimens that resulted in dysgeusia contained platinum-based drugs. The patients who developed dysgeusia had higher controlling nutritional status scores at the start of chemotherapy compared to those who did not develop dysgeusia. In both subjective and objective assessments, the patients with dysgeusia performed significantly worse than those without dysgeusia. Six of the eight patients who developed dysgeusia were administered Novelzine, which did not improve the taste disorder despite the improvement of serum zinc levels.
Conclusion: The combined approach using subjective and objective taste assessment methods was useful in assessing chemotherapy-induced dysgeusia. Mechanisms other than hypozincemia should be considered as contributors to taste disorders caused by platinum-based drugs.
Keywords: Chemotherapy-induced dysgeusia; CiTAS; paper testing; serum zinc; taste test.
Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Conflict of interest statement
The Authors declare that there are no conflicts of interest regarding the publication of this paper.
Similar articles
-
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.Support Care Cancer. 2022 Jun;30(6):5351-5359. doi: 10.1007/s00520-022-06936-4. Epub 2022 Mar 15. Support Care Cancer. 2022. PMID: 35292848 Free PMC article.
-
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study.Support Care Cancer. 2022 Aug;30(8):6955-6961. doi: 10.1007/s00520-022-07091-6. Epub 2022 May 11. Support Care Cancer. 2022. PMID: 35538327
-
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.Oncologist. 2008 Mar;13(3):337-46. doi: 10.1634/theoncologist.2007-0217. Oncologist. 2008. PMID: 18378545 Clinical Trial.
-
The CiTAS scale for evaluating taste alteration induced by chemotherapy: state of the art on its clinical use.Acta Biomed. 2019 Jul 8;90(6-S):17-25. doi: 10.23750/abm.v90i6-S.8278. Acta Biomed. 2019. PMID: 31292411 Free PMC article. Review.
-
Pharmacological strategies and nutritional supplements for managing dysgeusia among chemotherapy patients: A systematic review.Clin Nutr ESPEN. 2024 Oct;63:20-30. doi: 10.1016/j.clnesp.2024.05.026. Epub 2024 Jun 12. Clin Nutr ESPEN. 2024. PMID: 38900642
References
-
- Wickham RS, Rehwaldt M, Kefer C, Shott S, Abbas K, Glynn-Tucker E, Potter C, Blendowski C. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum. 1999;26(4):697–706. - PubMed
-
- U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 2017. Available at: https://www.eortc.be/services/doc/ctc/ [Last accessed on May 20, 2023]
MeSH terms
Substances
LinkOut - more resources
Full Text Sources